Navigation Links
For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
Date:7/8/2009

WALTHAM, Mass., July 8 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the treatment of dyslipidemia patients who fail to reach LDL goal, surveyed physicians are increasingly switching patients to a more potent statin --- most notably AstraZeneca's Crestor --- rather than adding Merck/Schering-Plough's Zetia (ezetimibe) or switching to Merck/Schering-Plough's Vytorin (simvastatin/ezetimibe). These changes have occurred as a result of the JUPITER trial as well as the ENHANCE and SEAS trials.

The new Physician & Payer Forum report entitled Vytorin One Year On: How Will Prescriber Attitudes and Payer Hurdles Influence the Markets for Dyslipidemia? finds that the share of patients prescribed Vytorin and Zetia by surveyed PCPs in primary prevention has declined by three and one percentage point respectively since the conclusion of the ENHANCE and SEAS clinical trials. However, in primary prevention, the share of patients prescribed Vytorin and Zetia by cardiologists has declined by seven and four percentage points respectively during the same time period.

The report also finds that a majority of managed care organizations' (MCOs) pharmacy directors have taken action as a result of the SEAS and ENHANCE trials. The ENHANCE trial showed that Vytorin was no more effective than the less expensive generic simvastatin in reducing carotid intima-media thickness. The report's survey results indicate that Vytorin was moved to a less favorable tier in 30 percent of both commercial plans and Medicare PDPs, although these actions may have been based on some misconceptions about Vytorin's efficacy.

"Although two-thirds of surveyed pharmacy directors indicate that they are aware of the results of the ENHANCE trial, their understanding of the results appears somewhat flawed and favors simvastatin," said Decision Resources Analyst Jeremy Goldman, M.D. "Only one-quarter of all surveyed pharmacy directors know that ENHANCE showed Vytorin was more effective at reducing LDL cholesterol than simvastatin. The negative press surrounding the results of the ENHANCE trial appears to have left an incorrect and unfavorable impression about Vytorin on many MCO pharmacy directors."

Vytorin One Year On: How Will Prescriber Attitudes and Payer Hurdles Influence the Markets for Dyslipidemia? is based on a U.S. survey of 70 primary care physicians, 70 cardiologists and 20 MCO pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                        Decision Resources, Inc.
    Christopher Comfort                       Elizabeth Marshall
    781-296-2597                              781-296-2563
    ccomfort@dresources.com                   emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. National Survey: Americans Fear Paying for Cancer Treatment As Much As Dying of the Disease
2. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
3. U.S. Food and Drug Administration and Xanodyne Agree on a Plan to Keep Propoxyphene-Containing Products Available as Treatment Options for the Management of Mild to Moderate Pain
4. Rice University teams award-winning device could benefit treatment of hand injuries
5. June 2009 Mayo Clinic Health Letter Highlights Probiotics, Carotid Artery and Breast Cancer Treatments
6. New strategies to improve treatment and ultimately prevent heart failure in children
7. ICSI Plans Symposium on New Depression Treatment Program That Is Improving Patient Outcomes Five-Fold Over Typical Primary Care
8. Major Firms Eyeing CBMS Development of New Glaucoma Treatment
9. New, More Effective Acne Treatment Program Launches
10. Toronto researchers discovery points to a new treatment avenue for acute myeloid leukemia
11. Ophthalmologists Invited To Participate in Betadine for EKC Treatment Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... May 06, 2016 , ... The National Association of Chain ... in Puerto Rico. Radio messages set to debut on Monday, May 9, and ... about ways to protect themselves and their unborn children from the effects of ...
(Date:5/6/2016)... ... May 06, 2016 , ... DrugDev President ... the way the pharmaceutical industry conducts clinical trials. This month Ibs was named No. ... in pharma, and he was honored as a Tech Disruptor by the Philadelphia Business ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... Integration Service, their latest implementation service offering for global clients of Coupa ( ... ). , Bluvault’s Integration Service is a key component in the suite ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, EarQ ... the unique opportunity to learn more about Signia’s technology and the successful business and ... is our priority to see practices succeed in this highly competitive industry,” said Ed ...
(Date:5/6/2016)... ... May 06, 2016 , ... Multiple award winning plumbing company in ... 35 years. Maintaining core values of exceptional customer service, quality work at reasonable rates, ... leading name in San Diego plumbing, and other services including heating & air conditioning ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... , First quarter 2016 adjusted diluted earnings per share ... , First quarter reported diluted (GAAP) loss per share ... revises 2016 financial guidance; now expects 2016 revenues to range ... non-GAAP earnings per share to range from $4.50 to $4.80 ... and manufacturing facility restructuring , Company expands ...
(Date:5/5/2016)... Calif. , May 5, 2016  Diagnostic ... a decade due to concerns that these tests ... the approach to imaging, as well as the ... new era of medical peripherals that help health care providers ...   Ampronix  advanced medical imaging is a renowned authorized ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... for PET Imaging in Top 5 EU Markets"  report to ... This report provides information on the current Positron Emission ... Five European Markets (T5 EU), which includes France ... , Spain and the ...
Breaking Medicine Technology: